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Abstract: A common pathophysiological course in vascular diseases is an overwhelming 
activation and aggregation of blood platelets, which results in atherothrombosis. By causing 
the last decisive step of cerebral, coronary, or peripheral arterial ischemia thrombotic com-
plications of atherosclerotic disease represent a major player in death cause statistics of most 
western countries. The development of novel therapies against platelet-dependent thrombosis 
and the concurrent improvement of existing therapeutic strategies thus is a paramount focus of 
pharmaceutical research. Currently, efﬁ  ciency, dosing and indications of established antiplatelet 
substances are being re-evaluated, whilst new, so far unrecognized molecular targets for inhibi-
tion of platelet activity come up front. This not only allows for interesting new therapeutical 
options, but also widens our insight into the role platelets play in atherosclerosis in general. 
This article summarizes the relevant pathophysiology of platelet activation, presents current 
concepts in antiplatelet drug therapy, and highlights the role of platelets in vascular diseases 
apart from atherothrombosis.
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Introduction
Pathophysiology of platelet activation in atherothrombosis
Platelet activation within a blood vessel that is altered by atherosclerosis consists of 
numerous single steps originating with an initial transient interaction of the platelet 
with the still intact endothelium. On atherosclerotically activated endothelium, this 
may be followed by ﬁ  rm interaction with intact endothelium, but ultimately leads 
to a cascade of events resulting in thrombotic occlusion of a the blood vessel when 
platelets ﬁ  rmly adhere and become activated at sites of ruptured endothelium. This 
last event then causes myocardial infarction when a coronary artery is affected (Fuster 
et al 1992) and other catastrophes associated with atherothrombosis, depending on the 
location involved. In all these processes, endothelial and platelet adhesion receptors, 
platelet born activatory receptors, endothelium-released anti- and pro-platelet factors, 
platelet-released auto-activatory factors, and components of the subendothelial matrix 
each have their speciﬁ  c roles. Based on the detailed characterization of these single 
steps and factors involved in platelet activation, the development of novel antiplatelet 
drugs aims at speciﬁ  cally targeting some of these entities.
According to our current understanding of pathophysiology within blood vessels, it 
is assumed that under conditions of arterial blood ﬂ  ow, an initial contact of a circulat-
ing platelet with the intact endothelium is mediated either through von-Willebrandt 
Factor (vWF) or the endothelial surface molecule P-selectin, which both are involved 
in rolling of the platelet at the subendothelium (Jackson et al 2003). Following plate-
let rolling, the next escalation of platelet activation is also mediated by vWF, which, 
through ﬁ  rmly binding to the platelet GPIb receptor also mediates the ﬁ  rst ﬁ  rm adhe-
sion (Jackson et al 2003; Ruggeri 2003). This initial reversible interaction may already Vascular Health and Risk Management 2008:4(3) 638
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lead to preactivation of platelets in terms of platelet release 
of factors that either mediate platelet auto-activation, such as 
adenosine diphosphate (ADP) or thromboxane A2 (TxA2), or 
these factors that have vasoactive properties such as epineph-
rine, serotonin, CD40 ligand (CD40L), and others. Finally, 
at sites of ruptured endothelium, collagen ﬁ  brils contained 
in the subendothelial matrix gain contact with ﬂ  owing blood, 
an important step in longer lasting platelet activation, which 
goes along with platelet shape change, intracellular calcium 
elevation, and release of contents of platelet granules, which 
contain the already mentioned auto-activatory and vasoactive 
substances (Siess 1989; Jackson et al 2003; Nieswandt and 
Watson 2003; Ruggeri 2003).
Platelets possess various receptors for collagen, such 
as the GPIa/IIa integrin, which mediates ﬁ  rm adhesion or 
the GPVI receptor, which, according to discoveries made 
during the last ten years, mediates strong platelet activation 
(Nieswandt and Watson 2003). The latter seems to represent 
the decisive step leading to profound platelet activation with 
its sequele of the aggregation cascade and the ultimate throm-
botic occlusion of a vessel following injury to its wall.
Especially the release of auto-activating ADP and TxA2 
sustain the cascade of aggregation once it is initiated eg, 
by collagen. These factors lead to activation of further, not 
yet activated platelets and to their recruitment to the site of 
aggregation. Platelet receptors for ADP are the purinergic 
P2Y1 and P2Y12 receptors, each of which activates speciﬁ  c 
signaling pathways. Whilst the P2Y1 receptor is involved in 
shape change and a transient type of aggregation, the P2Y12 
receptor is the target molecule of thienopyridine drugs and 
physiologically mediates sustained aggregation (Daniel et al 
1998; Jin et al 1998; Dorsam and Kunapuli 2004). On the 
other hand, TxA2 activates platelets through the TP pros-
tanoid receptor, which initiates a cAMP dependent signaling 
cascade (Siess 1989).
A necessary precondition for the binding of two platelets 
to each others and thus for platelet aggregation following the 
initial receptor ligand interaction dependent activation, is 
the presence of numerous mechanical platelet receptors, the 
GPIIb/IIIa integrin receptors (Shattil 1995). They function 
as ﬁ  brinogen receptors and mediate binding of two platelets 
through one molecule of ﬁ  brinogen. By breaking down 
ﬁ  brinogen to ﬁ  brin, thrombin then manifests the irrevers-
ibility of binding of two platelets two each others, as until 
then aggregation is a reversible phenomenon. By this action, 
thrombin also has a central role in thrombus formation and 
itself is the most potent amongst the pathophysiologically 
relevant platelet activators (collagen, ADP, TxA2, thrombin, 
to a lesser degree also epinephrine and others) (Jackson et al 
2003; Shankar et al 2006) (Figure 1).
A role for platelets in atherosclerosis 
beyond thrombosis
Apart from dissecting the single steps of platelet activation 
and thus contributing to innovative therapeutical strategies 
targeting atherothrombosis, platelet research nowadays has 
come up with a plethora of evidence for an involvement of 
platelets in inﬂ  ammatory and proatherogenic pathophysi-
ological vascular processes ( Huo et al 2003; Gawaz et al 
2005). Other data point to the fact that platelets might con-
tribute to angiogenesis through secretion of granule contents 
(Pinedo et al 1998). These insights allow the implication that 
antiplatelet therapies in the future might not only be useful 
for preventing atherothrombosis, but may also positively 
influence the progression of atherosclerosis in general. 
In this case, data pointing at a use of certain antiplatelet 
substances in primary prevention, such as present at least 
for aspirin, could be brought to a new light and extend the 
scope of indications of antiplatelet therapies. Of note, there 
repeatedly have been observations about a use of low-dose 
aspirin in primary prevention of certain solid tumors, which 
on a speculative base could be in connection with a potential 
proangiogenic effect of platelet secreted mediators such as 
platelet-derived growth factor (Dube et al 2007). However 
these assumptions so far remain speculative and need further 
backup by clinical or experimental evidence.
Clinically established antiplatelet 
strategies
Low-dose aspirin
Aspirin inhibits activation of the enzyme cyclooxygenase 
and thus cyclooxygenase-dependent formation of autoacti-
vating TxA2 in platelets (Figure 2). It does so by irrevers-
ibly acetylating a serine residue within the active centre of 
the enzyme (Loll et al 1995). In anucleate cells, which do 
not contain mRNA and the cellular organelles for protein 
synthesis and thus cannot resynthesize for cyclooxygenase, 
such as in platelets, this leads to an inhibition of for as long 
as the speciﬁ  c platelet circulates (Evangelista et al 2006). 
As a single dose of low-dose aspirin only inhibits cyclo-
oxygenase incompletely, but as the accumulation caused 
by irreversible binding after repeated delivery leads to an 
effective inhibition, this inhibiting effect is quite speciﬁ  c for 
platelets, because nucleate cells overcome the accumulation 
of low-dose aspirin by novel synthesis of cyclooxygenase. Vascular Health and Risk Management 2008:4(3) 639
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Thus, there is a preferential inhibition for platelet cyclo-
oxygenase in comparison with cyclooxygenases of other 
vascular cells such as endothelial or smooth muscle cells, 
when low-dose aspirin is repeatedly delivered.
A beneﬁ  cial effect of aspirin that is related to inhibition 
of platelet activity has ﬁ  rst been suspected in the 50s of the 
past century (Craven 1953) and was ﬁ  rst described in the 
following decade by Weiss and colleagues (1968).
Rapid absorption following its intake and the mentioned 
irreversible binding to platelet cyclooxygenase lead to an 
inhibition of platelet function as soon as about one hour 
after intake of aspirin, an effect which lasts for several 
days (Patrono et al 2004). Repeated delivery increases the 
antiplatelet effect and a maximum effect is reached at about 
5 days following application of low-dose aspirin (Patrignani 
et al 1982; Cipollone et al 1997).
Clinical indications of low-dose aspirin span from 
primary to secondary prevention and also to acute treatment 
of atherothrombotic events (ISIS-2 Collaborative Group 
1988; Wallentin 1991; Nymanet al 1992). However, whereas 
the use in secondary prevention is uncontradicted, this is 
not clearly the case in primary prevention and especially 
with regard to gender or site of manifestation of the athero-
thrombotic event (cerebrovascular or coronaries) that is to be 
prevented, there are contradictory reports (Peto et al 1988; 
Physician’s Health Study Group 1989; Manson et al 1991; 
Thrombosis Prevention Trial Study Group 1998; Awtry 
and Loscalzo 2000; Antithrombotic Trialists’ Collaboration 
2002; Ridker et al 2005). In terms of gender, the larger ones 
of the studies addressing primary prevention with aspirin 
have enrolled mainly males, such as the Physicians’ health 
study (Physician’s Health Study Group 1989), which showed 
a strong decrease in the risk for myocardial infarction, or 
the British Physicians’ Study, which failed to do so (Peto 
et al 1988). Interestingly, aspirin for primary prevention of 
cardiovascular thrombosis did not decrease mortality, which 
could have been to a fairly low intrinsic risk within the study 
populations (Awtry and Loscalzo 2000). In contrast to this, 
Figure 1 Signaling pathways that activate platelets intraarterially. Platelets possess different receptors that are speciﬁ  c for physiological stimuli such as collagen, ADP, TxA2, 
thrombin, or vWF. Receptors for ADP are the purinergic P2Y1 and P2Y12 receptors, Collagen binds a GPIa/IIa integrin-receptor and activates platelets through the GPVI 
receptor. Thrombin activates via protease-activated receptors (PAR), of which 4 isotypes have been described. It also binds GPIb/V/IX, which is equally a receptor for vWF. 
TxA2 activates through the TP-receptor, a prostanoid-receptor (not shown are epinephrine and serotonin, which may also activate platelets in vivo). Following receptor medi-
ated platelet activation the platelet GPIIb/IIIa integrin receptor is activated and secreted from platelet granules, which ultimately mediates platelet-platelet binding through 
ﬁ  brinogen and thus is indispensable for aggregation. Other sequele of platelet activation include activation of platelet cyclooxygenase-1 (COX) which induces formation and 
release of auto-activating TxA2.
Abbreviations: ADP, adenosine diphosphate; TxA2, thromboxane A2; vWF, von-Willebrandt Factor.
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the Thrombosis Prevention Trial investigated a group of 
patients at higher risk, and was able to show that primary 
prevention by aspirin reduced the risk of ischemic heart 
disease in more than 5000 men (Thrombosis Prevention 
Trial Study Group 1998). This effect was not observed in a 
recently published prospective study in women, which failed 
to show that aspirin affects the risk of myocardial infarction 
or death from cardiovascular causes. However, in this study, 
there was a beneﬁ  cial effect on the risk of stroke (Ridker 
et al 2005). In contrast to this, a similar randomized study 
that had previously been performed in nurses taking aspirin 
infrequently, did show a positive effect in primary prevention 
of ﬁ  rst myocardial infarction (Manson et al 1991).
There have repeatedly been reports about a “resistance” 
of certain patients to aspirin with respect to its antiplatelet 
efﬁ  cacy (Wang et al 2006). Indeed, there can be situations 
in which low-dose aspirin therapy is ineffective. There are 
for example numerous indications that aspirin may be less 
effective in certain patient groups at high risk for vascular 
events, such as in diabetics (Angiolillo et al 2005; Coccheri 
2007). Speciﬁ  c interactions of other drugs with the active 
centre of cyclooxygenase that aspirin also binds to, can 
reduce aspirin efﬁ  ciency. This can be the case when some 
nonsteroidal anti-inﬂ  ammatory drugs, which do not necessar-
ily exhibit the same antiplatelet activity as aspirin, are taken 
before aspirin is ingested. Other reasons for insufﬁ  cient efﬁ  -
ciency of aspirin are reduced absorption after oral ingestion, 
extra-platelet TxA2 formation (eg, in vascular smooth muscle 
cells) or genetic variabilities in cyclooxygenase sensitivity 
to aspirin (Patrono and Rocca 2007). In no case, however, 
there is an underlying resistance in a pharmacological sense, 
which would mean a loss of sensitivity after initial exposure 
to the drug. Decreased aspirin efﬁ  ciency is always caused 
by either individual factors or by speciﬁ  c pathophysiological 
situations. Thus, the term ‘resistance’ is incorrect.
Nevertheless, altogether, daily intake of low-dose aspirin 
represents the best established, safest and cheapest strategy 
for prevention of atherothrombotic events such as myocardial 
infarction or stroke, with lesser data at hand dealing with the 
prevention of peripheral thrombotic events.
Figure 2 Established antiplatelet substances. Thienopyridines such as ticlopidine or clopidogrel need to be hepatically converted into an unknown active metabolite in order 
to exert antagonistic action at the P2Y12 ADP receptor. Aspirin acts as an irreversible inhibitor of cyclooxygenase (COX), which leads to a decreased production of platelet 
TxA2. GPIIb/IIIa Inhibitors in contrast prevent a mechanic event in platelet activation, which is the binding of ﬁ  brinogen, the most important prerequisite for platelet-platelet 
binding and thus aggregation. GPIIb/IIIa inhibitors are either monoclonal antibodies (Abciximab) or peptides of low molecular weight (Eptiﬁ  batide, Tiroﬁ  ban). (Not shown are 
the antiplatelet drugs dipyridamol, which is contained in Aggrenox™, or cilostazol, both inhibitors of phosphodiesterases).
Abbreviation: ADP, adenosine diphosphate.
Collagen
PAR
P2Y1 GPIa-IIa GPVI
TP
Fibrinogen Aggregation
ADP
COX
Different, receptor-
specific pathways
GPIIb-IIIa
Thienopyridines
(Ticlopidin, Clopidogrel)
P2Y12
Aspirin
GPIIb/ IIIa Inhibitors
(Abciximab, Tirofiban, Integrilin)
GPIb
GPV
GPIX
vWF
Thrombin
Thromboxan A2Vascular Health and Risk Management 2008:4(3) 641
Antiplatelet drugs in cardiological practice
Dipyridamole, an inhibitor of nucleoside transport that 
inhibits platelet activation by increasing adenosine levels, is 
being used in a ﬁ  xed combination with aspirin as an antiplatelet 
agent (Schaper 2005). Although this combination has been 
shown to be superior to aspirin alone in secondary prevention of 
vascular thrombotic events following stroke in the ESPRIT trial 
(Halkes et al 2006), this effect could not been extended to other 
atherothrombotic diseases so far (De Schryver et al 2007).
ADP receptor blockade: Thienopyridines
As mentioned, the release of autoactivating substances such 
as TxA2 or ADP is an important step in the ampliﬁ  cation of 
platelet activation leading to complete aggregation. ADP 
activates platelets by binding its purinergic P2Y1 and P2Y12 
receptors. Whereas stimulation of the P2Y1 receptor medi-
ates calcium mobilisation, shape change and a transient, 
reversible form of aggregation, stimulation of the P2Y12 
receptor induces lasting aggregation and a decrease in cAMP 
(Cattaneo 2007).
Thienopyridines, which were known to inhibit platelet activ-
ity before the underlying mechanism was discovered, are antago-
nists at the P2Y12 receptor (Figure 2). Currently two substances 
are available: Clopidogrel and the older drug ticlopidine, which, 
due to its side effects, has been largely driven off the market. 
Both substances are prodrugs that have an active metabolite, 
which is only liberated after hepatic metabolism by the cyto-
chrome P450 3A4 (CYP3A4) system. This so far unknown 
metabolite then irreversibly binds the P2Y12 receptor.
The efﬁ  ciency of thienopyridines in the treatment of 
atherothrombotic disorders was ﬁ  rst described for ticlopi-
dine, which proved to have similar outcomes as aspirin in 
unstable angina (Balsano et al 1990). Moreover, it showed 
to have additional beneﬁ  t in combination with aspirin in 
preventing stent thrombosis (Eshaghian et al 2007). Later, 
when the CLASSICS study showed comparable efﬁ  ciency 
for the second thienopyridine, clopidogrel, with markedly 
reduced rates of side effects, namely a lack of dangerous 
thrombocytopenia in comparison to ticlopidine, the clinical 
use of ticlopidine was thrust into the background and clopi-
dogrel prevailed (Bertrand et al 2000).
The ﬁ  rst large randomized study assessing the efﬁ  ciency 
of clopidogrel, the so called CAPRIE study, compared a 
monotherapy of clopidogrel versus aspirin in secondary 
prevention of atherothrombotic diseases. The CAPRIE 
study proved the effectiveness of clopidogrel, which, when 
compared with aspirin even afforded a statistically signiﬁ  cant 
reduction of cumulative atherothrombotic events at 36 
month follow-up. (CAPRIE Steering Committee 1996). 
Only because of markedly more expensive daily costs, these 
data did not lead to a displacement of aspirin as the drug of 
ﬁ  rst choice in secondary prevention of cardiovascular events, 
so that in clinical practice clopidogrel as a monotherapy is 
merely used as an alternative of second choice to aspirin. 
Thus, clopidogrel so far is mainly used in the settings of acute 
coronary syndromes, myocardial infarction, and as a partner 
of aspirin in the so called dual antithrombotic therapy regimen 
following coronary angioplasty. Numerous studies, such as 
CURE, PCI-CURE, CREDO, COMMIT or CLARITY-TIMI 
28 have underscored the usefulness of a dual antiplatelet 
therapy with aspirin and clopidogrel in the post-procedural 
treatment of coronary angioplasty (Eshaghian et al 2007). 
Interestingly, the CHARISMA study also tested the dual 
antiplatelet regimen in the setting of primary prevention and 
was not able to show additional beneﬁ  t in this clinical setting 
in comparison to aspirin alone (Bhatt et al 2006). It needs to 
be mentioned that a dual antiplatelet therapy with aspirin and 
clopidogrel failed to prove superior to clopidogrel alone in 
the secondary prevention of ischemic cerebrovascular events 
in the MATCH study (Diener et al 2004).
More recently, there have been intensive attempts to 
maximize the efﬁ  ciency of clopidogrel treatment by estab-
lishing an optimized dosing. This has led to an increase of 
the initial loading dose from 300 mg to 600 mg and has also 
prompted the setup of trials such as the CURRENT study, 
which investigate the increase of a maintenance daily dose 
from 75 mg to 150 mg. Smaller studies in healthy volunteers 
suggest that this increase in maintenance dose might also 
enhance the antiplatelet properties of clopidogrel (Angiolillo 
et al 2007; von Beckerath et al 2007).
Another recent focus of periinterventional drug treatment 
with clopidogrel has been the optimal duration of postinterven-
tional dual antiplatelet therapy. This has been prompted by the 
enormous clinical success of drug-eluting stents in the ﬁ  rst years 
after introduction of these devices into therapy. Although it cur-
rently cannot be taken as a fact that drug-eluting stents increase 
the rates of late stent thrombosis, as has been suggested by many 
observations (Mauri et al 2007), it can be stated that an extension 
of the duration of antiplatelet therapy following percutaneous 
coronary intervention leads to a signiﬁ  cant reduction of the risk 
for death or myocardial infarction (Eisenstein et al 2007), an 
effect, which could already be observed in some studies with 
bare-metal stents such as CREDO or PCI-CURE. More recent 
data show clearly that a profound success of coronary stenting 
not only in the context of drug-eluting stents, will critically 
depend upon the establishment of a feasible, safe and cheap 
postinterventional antiplatelet therapy (Stone et al 2007).Vascular Health and Risk Management 2008:4(3) 642
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Similarly described for aspirin, there also have been 
discussions about a potential resistance of certain patients 
to clopidogrel (Wang et al 2006). Also in case of clopido-
grel, the term ‘resistence’, however, is inappropriate in this 
context, because the effects that have been observed are 
more likely because of eg, a decreased sensitivity of some 
patients to the clopidogrel effects. Other potential reasons 
for clopidogrel inefﬁ  ciency can be diminished bioavailability 
of the active metabolite due to pharmacological interaction 
with other CYP3A4 metabolized drugs or inappropriate 
dosing when 75 mg/day are taken. Situational factors, such 
as increased platelet activity in smokers, diabetics or hyper-
cholesterolemic patients aggravate the situation (Eshaghian 
et al 2007; Maree and Fitzgerald 2007).
GPIIb/IIIa receptor blockade
Nowadays, blockade of the most important and highly 
expressed platelet receptor, the ﬁ  brinogen-binding integrin 
receptor GPIIb/IIIa (or ανβ3-Integrin) is an indispensable 
part of interventional treatment of acute coronary syndromes 
(Figure 2). In additional to acute coronary syndromes, the 
three clinically available intravenous GPIIb/IIIa inhibitors 
abciximab (chimeric monoclonal antibody), eptiﬁ  batide and 
tiroﬁ  ban (both RGD-inhibiting peptides of low molecular 
weight) are also used as adjunct therapy in high risk coronary 
interventions (Kong et al 1998).
The mechanism of antiplatelet action of GPIIb/IIIa 
inhibitors differs from other antiplatelet drugs because of 
their mechanism of action; they do not necessarily inhibit 
the activation of single platelets. However, as blockade of 
ﬁ  brinogen-binding completely prevents the most crucial 
mechanical step in aggregation, these drugs have the stron-
gest antithrombotic potential. Still, GPIIb/IIIa inhibitors may 
not necessarily prevent platelet granule secretion or initial 
activation as eg, induced by collagen. This circumstance 
and underdosing or pharmacokinetic matters in respective 
studies may be have formed the basis for ineffectiveness 
of orally available GPIIb/IIIa inhibitors, which also caused 
increased bleeding and thus have no role in clinical practice 
today (Chew et al 2001).
It is interesting to note that – in contrast to aspirin and 
clopidogrel – resistances against or ineffectivenesses of 
GPIIb/ IIIa inhibitors have not been described so far.
New developments
Among the many new antiplatelet substances that are 
currently being developed, different new P2Y12 antagonists 
are most likely to soon be introduced into clinical routine. 
The third orally available Thienopyridine drug, prasugrel, 
and the two non-thienopyridine antagonists of P2Y12 can-
grelor (intravenous administration) and AZD6140 (orally 
applicable), are currently being tested in phase III studies 
or are already being launched by the manufacturers, after 
having shown promising results in phase II studies in terms 
of efﬁ  ciency and safety (Figure 3).
Similarly to clopidogrel, prasugrel is a prodrug, which 
only after hepatic metabolism releases its clinically active 
compound. In preclinical evaluation, it is 10 times more 
potent than other thienopyridines. Its safety and a compa-
rable efﬁ  ciency of prasugrel in comparison with clopidogrel 
(300 mg loading dose, 75 mg maintenance dose) was shown 
in the (JUMBO)-TIMI 26 study (Wiviott et al 2005). In the 
recently published TRITON-TIMI 38 study, prasugrel treat-
ment was associated with a signiﬁ  cantly reduced rate of the 
primary end point, which was death from cardiovascular 
causes, nonfatal myocardial infarction, or nonfatal stroke 
in patients with acute coronary syndromes, when compared 
with clopidogrel 300 mg loading and 75 mg maintenance 
dose. However, this advantage did not result in a difference 
in overall mortality, and, more importantly there was an 
increase in rates of major bleeding, including fatal bleed-
ing (Wiviott et al 2007). As the currently running phase III 
study (PRINCIPLE)-TIMI 44 also incorporates more up to 
date, increased doses of clopidogrel it will not only deliver 
important information about prasugrel, but will also provide 
valuable information about the clinical consequences of an 
increased dose of clopidogrel, which so far is not sufﬁ  ciently 
backed by data from large patient cohorts.
Cangrelor or AZD6140, on the other hand, are directly 
acting reversible inhibitors at the P2Y12 receptor. Potential 
advantages of cangrelor and AZD6140 in comparison to clop-
idogrel likely lie in their different pharmacokinetics, which 
include more rapid onset and loss of action (Greenbaum 
et al 2006). Due to this, cangrelor is also being investigated 
as an alternative to GPIIb/IIIa receptor antagonists in the 
CHAMPION-PCI and CHAMPION-PLATFORM studies, 
whereas AZD6140 is being tested against clopidogrel in the 
setting of STEMI and NSTEMI in the PLATO study. These 
drugs, due to the quicker loss of action, bear the potential to 
have improved safety proﬁ  le in speciﬁ  c clinical situations 
such as in the setup of perioperative coronary angioplasty.
Besides the newly developed P2Y12 receptor antago-
nists, there are antiplatelet strategies currently under 
development, which target structures of platelets that so 
far have not been subject to pharmacological treatment and 
thus truly incorporate innovative mechanisms of action. Vascular Health and Risk Management 2008:4(3) 643
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Examples are antibodies or aptamers that target the collagen 
receptor GPVI or the vWF receptor GPIb (Figure 3). Both of 
these targets have gained attention rather late in comparison 
to the above mentioned platelet receptors as therapeutic 
targets, yet due to the important role of these structures in 
platelet pathophysiology may pose interesting alternatives 
for treatment and even extent the scope of indications of 
antiplatelet drug. Moreover, in animal experiments, these 
antibodies not only have antiplatelet, but also antiathero-
sclerotic properties and also may be associated with lower 
bleeding risks (Kleinschnitz et al 2007).
Thromboxane receptors represent interesting targets 
for newly developed antiplatelet agents. Interestingly, in 
animal models, drugs like S18886, a selective thromboxane 
receptor antagonist, exert properties beyond inhibition of 
platelet aggregation, by also improving endothelial function 
(Belhassen et al 2003), or inhibiting atherosclerosis devel-
opment (Worth et al 2005). Although no clinical studies for 
S18886 are at hand yet, it seems to have excellent antithrom-
botic activity in an animal model of stent thrombosis (Vilahur 
et al 2007). Another substance that targets the thromboxane 
receptor also inhibits thromboxane synthase, and thus exerts 
dual inhibitory action. This drug, picotanide, has proved 
to be more effective than aspirin in the DAVID study that 
addresses its use in the prevention of mortality and major 
cardiovascular events in diabetics with peripheral arterial 
disease (Neri Serneri et al 2004).
Other interesting targets are the protease-activated recep-
tors (PAR), which are physiological targets of thrombin that 
are not only expressed on platelets, but also on endothelial and 
vascular smooth muscle cells and on macrophages (Figure 3). 
As experimental ﬁ  ndings have shown that PAR-dependent 
thrombin actions not only include platelet activation, but also 
the development of intimal hyperplasia, regulation of vessel 
tone, inﬂ  ammation and endothelial barrier function, the vari-
ous drugs that are currently being developed to target these 
structures, could potentially not only afford antithrombotic, 
but different, more profound antiatherosclerotic actions in 
patients (Leger et al 2006).
Conclusion
Antiplatelet therapy has come to be a main pillar in treatment 
of atherosclerosis. Well-established antiplatelet strategies 
include aspirin, one of the oldest and best-described 
Figure 3 Potential new targets of antiplatelet substances. Aside from the development of further P2Y12 ADP receptor antagonists, which are either thienopyridines or non-
thienopyridine structured and may have improved efﬁ  cacy and advantageous pharmacokinetics, there are receptors for important physiological platelet agonists that clinically 
have not been targeted yet, but represent structures with potential for pharmacological development, due to insights from experimental studies. Amongst these are the platelet 
collagen receptor GPVI, the GPIb receptor and thrombin binding protease activated receptors (PAR). Substances against the latter are already in preclinical testing.
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drugs at hand, as well as clopidogrel or GPIIb/IIIa inhibi-
tors, which both have become essential for periinterventional 
cardiology. New developments that are being tested either in 
clinical studies or are still in experimental preclinical phases 
include either alternative P2Y12 inhibitors or drugs that attack 
completely new targets. In any case, the concurrent progress 
in pathophysiological insights into platelet pathophysiology 
will likely bring about interesting even more new targets 
for antiplatelet substances. Similarly, it will continue to be 
of paramount importance to optimise existing antiplatelet 
strategies. In the near future, it will be exciting to witness the 
clinical impact of newly developed antiplatelet substances 
that currently are either in clinical testing or in still preclini-
cal phases. Due to their innovative molecular targets or new 
pharmacokinetics, clinical situations in which they may make 
sense can easily be imagined.
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